{"analyses":[{"groupIds":["OG000"],"nonInferiorityComment":"P value was based on the exact binomial test against the null hypothesis of ORR = 30% with alternative of ORR \\> 30%","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Binomial exact method"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.56","upperLimit":"79.11","value":"68.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by an IRC using the Lugano Classification","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 2.5 months","title":"Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}